Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Key abstracts being presented at ASH 2017

Anas Younes • 8 Dec 2017
ASH 2017
Follicular Lymphoma Hodgkin Lymphoma Mantle Cell Lymphoma Acalabrutinib Atezolizumab Brentuximab vedotin Dexamethasone Ibrutinib Rituximab
ECHELON-1 Lyma

The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, showcased the most cutting-edge data in the field of hematology by research groups from all over the world. Speaking from the conference, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the most anticipated data to be presented. These include details of the ECHELON-1 trial (NCT01712490), the efficacy of acalabrutinib in relapsed mantle cell lymphoma, follow up data on the LyMa trial (NCT00921414), and an evaluation of current PET scanning practices.

More from Anas Younes

Fimepinostat with venetoclax in R/R lymphoma
1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
Atezolizumab plus R-CHOP in DLBCL: encouraging results
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Related Videos

Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Changing community practice in FL: bispecific antibody delivery and treatment selection
2:44
Changing community practice in FL: bispecific antibody delivery and treatment selection
Kim Linton • 11 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals